Related Experiment Video
Updated: Jul 13, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
[Cardiac valvulopathy and dopamine agonist]
1Servicio de Neurologia, Hospital General Universitario Gregorio Marañon, Madrid, Spain. frandasp@meditex.es
Dopamine agonist treatment, particularly with ergot derivatives, may increase the risk of cardiac valvulopathy in Parkinson's disease patients. Discontinuation of these drugs can lead to improved valve function.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Investigated the association between dopamine agonist therapy and cardiac fibrotic valvulopathy in Parkinson's disease patients.
- Systematic review of published literature on this specific drug-induced valvulopathy.
Discussion:
- Cardiac valvulopathy identified in patients using ergot-derived dopamine agonists like pergolide, cabergoline, and bromocriptine.
- No reported cases of valvulopathy linked to non-ergot dopamine agonists.
Key Insights:
- Cumulative dose and treatment duration are probable risk factors for developing valvulopathy.
- Discontinuation of ergot-derived dopamine agonists may result in improved valve regurgitation.
Outlook:
- Further research needed to elucidate mechanisms and long-term effects.
- Clinical vigilance recommended for patients on dopamine agonists, especially ergot derivatives.
- Exploration of safer alternatives for Parkinson's disease management.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Heart Failure Drugs: Inotropic Agents
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Cardiomyopathy II: Dilated Cardiomyopathy
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Parkinson Disease ll: Pathophysiology

